Biosketch 

Sandra P. Susanibar Adaniya

I am a hematology-oncologist committed to a career in clinical and translational research in Multiple Myeloma (MM). My overarching goal is to improve the health outcomes of patients with MM by focusing on the identification of immune surveillance mechanisms to prevent myeloma relapse.

I attended medical school in Peru and, driven by my desire to pursue a career in malignant hematology, I migrated to the US. I completed my internal medicine residency at the University of Arkansas for Medical Sciences (UAMS), where I was appointed chief resident. Following my residency, I joined the Myeloma Institute at UAMS as a hospitalist. In this role, I participated as a sub-investigator in MM clinical trials and contributed to several research projects, including those on plasma cell leukemia, the use of minimal residual disease (MRD) in myeloma patients at different treatment stages, and the identification and management of infectious complications in MM.

During my fellowship at the University of Pennsylvania, I pursued formal mentored clinical and translational research through a Master in Science and Translational Research Program under the guidance of Drs. Alfred Garfall and Gerald Linette. The formal coursework, grantmanship workshop, and laboratory components of the master's program equipped me with the skills necessary to design and conduct hypothesis-driven clinical trials.

As faculty, I have focused on identifying mechanisms of immune surveillance associated with long-term disease control in MM and its precursor diseases: monoclonal gammopathy of unknown significance (MGUS) and smoldering multiple myeloma (SMM). Additionally, I have extensive experience as an investigator in clinical trials involving patients with newly diagnosed and relapsed refractory MM.